PURPOSE: This multicenter, randomized, double-blind, active-control study was designed to determine whether a single subcutaneous injection of pegfilgrastim (SD/01, sustained-duration filgrastim; 100 ...
The US Food and Drug Administration (FDA) has expanded the indication for tbo-filgrastim (Granix, Teva), now allowing it to be self-administered by patients and their caregivers. Tbo-filgrastim, a ...
The FDA has approved Aphexda plus filgrastim for the mobilization of hematopoietic stem cells in patients with multiple myeloma. The Food and Drug Administration (FDA) has approved Aphexda ...
The combination therapy is the first FDA approved for the mobilization of hematopoietic stem cells prior to autologous transplantation in patients with multiple myeloma. The FDA approved motixafortide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results